viimane versioon :
19/11/2024
antibiootikum   Penicillin G sodium  
Süsteravim
Stabiilsus lahustes Stabiilsust mõjutavad tegurid stabiilsust mõjutavad faktorid Sobimatus Manustamis viis Viited pdf
   keemiline struktuur  

Kaubanduslikud nimed erinevates maades   Kaubanduslikud nimed erinevates maades     

Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist

Benapen Brasiilia
Bencilpenicilina Ecuador, Maroko, Tšiili
Benpen Austraalia, uus-Meremaa
Bensylpenicillin Rootsi
Benzapen Iraan
Benzatec Lõuna Aafrika Vabariik
Benzatron Brasiilia
Benzylpenicillin Egiptus, Norra, Rootsi, Soome, Taani
Benzylpenicilline Tuneesia
Biconcillina Ecuador
Crystapen Iirimaa, Kanada, Suurbritannia
Declin Mehhiko
Fortepen Saudi Araabia
Geepenil Soome
Natrium penicillin G Holland
Novopen Lõuna Aafrika Vabariik
Pebencil Venetsueela
Penbendox Mehhiko
Penibiot Hispaania
Penicillin Norra
Penicillina G sodica Argentiina, Ecuador, Kolumbia, Portugal, Tšiili
Penilevel Hispaania
Sodiopen Hispaania
Unicillina Hispaania
Viited   Süsteravim   Viited : Penicillin G sodium  
tüüp avaldamine
13 ajaleht Stiles ML, Allen LV.
Stability of nafcillin sodium, oxacillin sodium, penicillin G potassium, penicillin G sodium and tobramycin sulfate in polyvinyl chloride drug reservoirs.
Am J Health-Syst Pharm 1997 ; 54: 1068-1070.
440 ajaleht Stiles ML, Tu YH, Allen LV.
Stability of cefazolin sodium, cefoxitin sodium, ceftazidime, and penicillin G sodium in portable pump reservoirs.
Am J Hosp Pharm 1989 ; 46: 1408-1412.
1057 ajaleht Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207.
1072 ajaleht Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA.
Compatibility of levofloxacin with 34 medications during simulated Y-site administration.
Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1241 ajaleht Rayani S, Jamali F.
The stability of penicillin G sodium in 5% dextrose in water minibags after freezing.
Can J Hosp Pharm 1985 ; 38: 162-163.
1263 ajaleht Allwood MC, Brown PW.
The effect of buffering on the stability of reconstituted benzylpenicillin injection.
Int J Pharm Pract 1992 ; 1: 242-244.
1725 ajaleht Oliver C, Law S.
Compatibility of oxytocin, zidovudine, and penicillin G.
Can J Hosp Pharm 2001 ; 54: 112-113.
2056 ajaleht Vella-Brincat JWA, Begg EJ, Gallagher K, kirkpatrick CMJ, Zhang M, Frampton C, Chambers ST.
Stability of benzylpenicillin during continuous home intravenous therapy.
J Antimicrob Chemother 2004 ; 53: 675-677.
2087 ajaleht Ferreira E, Forest JM, Hildgen P.
Compatibility of dimenhydrinate injectable by Y administration.
Pharmactuel 2004 ; 37: 17-20.
2090 ajaleht Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196.
3012 ajaleht Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220.
3227 ajaleht Simon B, Hancu G, Gy?resi A.
Application of capillary electrophoresis to the simultaneous determination and stability study of four extensively used penicillin derivatives
Braz J Pharm Sci 2014 ; 50, 3 : 521-527.
3520 Labor Cidomycin - Summary of product Chracteristics.
Sanofi 2011
3529 Labor Ciprofloxacin – Summary of Product Characteristics
Hospira 2013
3540 Labor Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010
3549 Labor Amikacine B Braun - Résumé des caractéristiques du produit.
B Braun 2012
3580 Labor Cytarabine Accord - Résumé des caractéristiques du produit
Accord Healthcare France 2016
3585 Labor Benzylpenicillin sodium - Summary of Product Characteristics
Genus Pharmaceuticals 2008
3643 Labor Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics
Sanofi 2015
3648 ajaleht Hossain M.A, Friciu M, Aubin S, Leclair G.
Stability of penicillin G sodium diluted with 0.9% sodium chloride injection or 5% dextrose injection and stored in polyvinyl chloride bag containers and elastomeric pump containers.
Am J Health-Syst Pharm 2014 ; 71:669-673.
3674 Labor Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016
3702 ajaleht McDougall D.A.J, McWhinney.
Stability of buffered benzylpenicillin solutions for outpatient parenteral antimicrobial therapy.
J Pharm Pract and Res 2014 ; 44, 1: 26-28.
3931 Labor Trimébutine (Débridat®) - Résumé des caractéristiques du produit
Pfizer Laboratoire 2016
3964 ajaleht Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33.
4154 Labor Bleomycin sulfate- Summary of Product Characteristics
Accord Health Care 2018
4319 ajaleht Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4389 ajaleht Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.
Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine.
Pharmactuel 2019 ;52,4:206-213
4590 ajaleht Smith E.K, McWhinney MPhil B.C.
Stability of buffered benzylpenicillin and flucloxacillin for a paediatric outpatient parenteral antibiotic therapy service.
J Pediatr Pharmacol Ther 2021 ; 51: 231-237.
4603 ajaleht Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4831 ajaleht Nezvalova-Henriksen K, Huseby Holm T, Nilsson N, Kjønniksen I, Tho I.
Frequently acquired drugs in neonatal intensive care and their physical compatibility.
Acta Paediatr 2022 ;111:2307–2314. 
4837 ajaleht De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page‑Sharp N, Moore B.R, Batty K.T.
Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings.
Eur J Clin Pharmacol 2024 ; 80:1079–1087.

  Mentions Légales